IDB 011
Alternative Names: IDB-011Latest Information Update: 21 Apr 2025
At a glance
- Originator IDBiologics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rift Valley fever
Most Recent Events
- 02 Apr 2025 Phase-I clinical trials in Rift Valley fever (Prevention) in USA (IM) (NCT06925919)
- 29 Jul 2024 Preclinical research in Rift Valley fever (Prevention) in USA (Parenteral) before July 2024 (IDBiologics pipeline, July 2024)
- 29 Jul 2024 Preclinical research in Rift Valley fever in USA (Parenteral) before July 2024 (IDBiologics pipeline, July 2024)